Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy - 10/09/11
Abstract |
Background: Chronotherapy studies with inhaled corticosteroids have shown optimal therapeutic benefit when steroids are administered four times per day (QID) or once daily at 3 PM.
Objective: This study evaluated whether more convenient once-daily dosage times (8 AM and 5:30 PM) produce improvement in asthma equivalent to QID.
Methods: Efficacy outcome measures included FEV1, peak expiratory flow rates, bronchial responsiveness, use of β2-agonists, nocturnal awakenings, and responses to a quality of life questionnaire. Systemic effects were blood eosinophil count, cortisol level, 24-hour urinary cortisol, and evaluation for oral candidiasis and dysphonia.
Results: Baseline measurements for all three treatment groups were similar. For morning peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.001) and the 5:30 PM group (p = 0.003), but not the 8 AM group (p = 0.75). For evening peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.005) and the 5:30 PM group (p = 0.01), but not for the 8 AM group (p = 0.47). There were significant improvements in all other outcome variables for each group except PC20. There was a significant improvement in PC20 only in the QID group. The systemic effects of the three regimens were comparable.
Conclusion: Dosing of inhaled steroid at 5:30 PM had no increased systemic effects and produced efficacy similar to QID dosing. Dosing at 8 AM did not produce results consistently comparable to QID dosing. Optimal once-daily dosing of inhaled steroid is between 3 PM and 5:30 PM.
Le texte complet de cet article est disponible en PDF.Keywords : Asthma, inhaled steroids, chronotherapy, dose timing, triamcinolone acetonide
Abbreviations : PEFR:, QID:, TA:
Plan
From the Department of Medicine, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center. |
|
Supported by grants from the Rhône-Poulenc Rorer Company and the National Jewish Medical and Research Center (General Clinical Research Center Grant M01RR00051). |
|
Reprint requests: Richard J. Martin, MD, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. |
|
1/1/85233 |
Vol 100 - N° 6
P. 771-774 - décembre 1997 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?